Ionis Pharmaceuticals, Inc. Common Stock

Ionis trades at a striking $12.4B valuation despite carrying no meaningful P/E ratio, suggesting the market is pricing in future profitability rather than current earnings power. The 10.99% short interest sits meaningfully above biotech averages, indicating skepticism exists despite the stock sitting at neutral RSI (52.8) and nowhere near its 52-week high. This positioning creates an interesting dynamic—the company appears neither oversold nor overbought technically, yet the substantial short float paired with an unprofitable current state suggests either significant execution risk ahead or potential for a squeeze if pipeline catalysts deliver. The gap between valuation ambition and present-day earnings reality leaves little room for disappointment.